{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:38:26Z","timestamp":1791041906960,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jpeds.2022.05.030","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T11:21:01Z","timestamp":1653045661000},"page":"81-88.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome"],"prefix":"10.1016","volume":"248","author":[{"given":"Taizo A.","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-2805","authenticated-orcid":false,"given":"Aparna","family":"Annam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Kulungowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"McCallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0021-1097","authenticated-orcid":false,"given":"Kathryn C.","family":"Chatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2022.05.030_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/15513815.2014.904026","article-title":"Twin infant with lymphatic dysplasia diagnosed with Noonan syndrome by molecular genetic testing","volume":"33","author":"Mathur","year":"2014","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ejhg.2015.175","article-title":"The lymphatic phenotype in Noonan and cardiofaciocutaneous syndrome","volume":"24","author":"Joyce","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jpeds.2022.05.030_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00247-018-04337-6","article-title":"Imaging of central lymphatic abnormalities in Noonan syndrome","volume":"49","author":"Biko","year":"2019","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib4","doi-asserted-by":"crossref","first-page":"e20200167","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2022.05.030_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.jpeds.2022.05.030_bib6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jpeds.2022.05.030_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejogrb.2018.10.019","article-title":"First trimester cystic hygroma colli: retrospective analysis in a tertiary center","volume":"231","author":"Schreurs","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7863\/jum.1989.8.2.59","article-title":"The prenatal sonographic features of Noonan's syndrome","volume":"8","author":"Benacerraf","year":"1989","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.jpeds.2022.05.030_bib9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/(SICI)1097-0223(199907)19:7<642::AID-PD610>3.0.CO;2-1","article-title":"Prenatal features of Noonan syndrome","volume":"19","author":"Nisbet","year":"1999","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jpeds.2022.05.030_bib10","doi-asserted-by":"crossref","first-page":"e13535","DOI":"10.1111\/petr.13535","article-title":"Cardiac transplantation in children with Noonan syndrome","volume":"23","author":"McCallen","year":"2019","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jpeds.2022.05.030_bib11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jpc.13889","article-title":"Octreotide for congenital and acquired chylothorax in newborns: a systematic review","volume":"54","author":"Bellini","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.jpeds.2022.05.030_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2022.05.030_bib13","series-title":"GeneReviews","first-page":"1993","article-title":"Noonan syndrome","author":"Allanson","year":"2001"},{"key":"10.1016\/j.jpeds.2022.05.030_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpdd.152","article-title":"Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors","volume":"4","author":"Cox","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jpeds.2022.05.030_bib15","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib16","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1097\/MPH.0000000000001819","article-title":"Trametinib-based treatment of pediatric CNS tumors: a single institutional experience","volume":"42","author":"Paul","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ahj.2012.04.018","article-title":"Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry","volume":"164","author":"Wilkinson","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jpeds.2022.05.030_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpeds.2022.05.030_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2022.05.030_bib20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2022.05.030_bib21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAFV600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jpeds.2022.05.030_bib23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41375-018-0169-y","article-title":"Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells","volume":"33","author":"Tasian","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jpeds.2022.05.030_bib25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jpeds.2022.05.030_bib26","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1172\/JCI71614","article-title":"Genetics of lymphatic anomalies","volume":"124","author":"Brouillard","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpeds.2022.05.030_bib27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1242\/dev.043489","article-title":"N- and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice","volume":"137","author":"Ichise","year":"2010","journal-title":"Development"},{"key":"10.1016\/j.jpeds.2022.05.030_bib28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/cr.2010.116","article-title":"VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis","volume":"20","author":"Zhang","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.jpeds.2022.05.030_bib29","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1093\/hmg\/ddy218","article-title":"Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly","volume":"27","author":"Li","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpeds.2022.05.030_bib30","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1002\/ajmg.a.35639","article-title":"Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome","volume":"158A","author":"Smpokou","year":"2012","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jpeds.2022.05.030_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2214\/ajr.134.2.399","article-title":"Lymphatic vessels dysplasia in Noonan's syndrome","volume":"134","author":"Hoeffel","year":"1980","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib32","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","article-title":"The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease","volume":"106","author":"Kratz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2022.05.030_bib33","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/MPH.0b013e3181e7571e","article-title":"Myeloproliferative disorder in Noonan syndrome","volume":"33","author":"Bastida","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jpeds.2022.05.030_bib34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-3476(97)70273-7","article-title":"Occurrence of myeloproliferative disorder in patients with Noonan syndrome","volume":"130","author":"Bader-Meunier","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2022.05.030_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jpeds.2022.05.030_bib36","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2022.05.030_bib37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2022.05.030_bib38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J Clin Invest"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347622004796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347622004796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:13:21Z","timestamp":1758359601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347622004796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"alternative-id":["S0022347622004796"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.05.030","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}